Список литературы
Кушлинский Н.Е., Красильников М.А. Биологические маркеры опухолей: фундаментальные и клинические исследования. М.: Издательство РАМН; 2017
Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., Yokose T., Jiang S.X., Inoue T., Nakagawa K., Tajima K., Nagai K. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J. Clin. Oncol. 2006; 24(1): 70-6.
Gustafson B.I., Kidd M., Chan A., Malfertheiner M.V., Modlin I.M. Bronchopulmonary neuroendocrine tumors. Cancer. 2008; 113(1): 5-21.
Travis W.D., Brambilla E., Burke A.P., Marx a., Nicholson A.G. WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC; 2015.
Rekhtman N. Neuroendocrine Tumors of the Lung: an update. Arch. Pathol. Lab. Med. 2010; 134(11): 1628-38.
Hendifar A.E., Marchevsky A.M., Tuli R. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. Journal of Thoracic Oncology. 2017; 12(3): 425-36.
Wolin E.M. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate Differentiated Neuroendocrine Tumors of the Lung. CHEST. 2017; 151(5):1141-6.
Kim J.Y., Hong S.-M., Ro J.Y. Recent updates on grading and classification of neuroendocrine tumors. Annals of Diagnostic Pathology. 2017; 29: 11-6.
Miękus N., Bączek T. Non-invasive screening for neuroendocrine tumors-Biogenic amines as neoplasm biomarkers and the potential improvement of “gold standards”. Journal of Pharmaceutical and Biomedical Analysis. 2016; 130: 194-201.
Korse C.M., Buning-Kager J.C.G.M., Linders T.C., Heijboer A.C., van den Broek D., Tesselaar M.E.T., van Tellingen O., van Rossum H.H. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clinica Chimica Acta. 2017; 469:130-5.
Chan D.L., Clarke S.J., Diakos C.I., Roach P.J., Bailey D.L., Singh S., Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumor’s. Critical Reviews in Oncology/Hematology. 2017; 113:268-82.
Buccheri G., Ferrigno D. Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase. Lung cancer. 2000; 30: 37-49.
Wong D.T. Salivary Diagnostics. Wiley-Blackwell: 2008.
Malathi N, Mythili S, Vasanthi HR. Salivary Diagnostics: A Brief Review. ISRN Dentistry. 2014; 2014:158786.
Miller C.S. Foley J.D., Bailey A.L., Campell C.L., Humphries R.L., Christodoulides N., Floriano P.N. Current developments in salivary diagnostics. Biomark. Med. 2010; 4(1): 171-89.
Nunes L.A., Mussavira S, Bindhu O.S. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review. Biochem. Med. (Zagreb). 2015; 25(2): 177-92.
Liu J., Duan Y. Saliva: A potential media for disease diagnostics and monitoring. Oral Oncology. 2012;48: 569-77.
Arunkumar S., Arunkumar J.S., Krishna N.B., Shakunthala G.K. Developments in diagnostic applications of saliva in oral and systemic diseases — A comprehensive review. Journal of Scientific and Innovative Research. 2014; 3(3): 372-87.
Shipper RG, Silletti E, Vingerhoeds MH. Saliva as research material: Biochemical, physicochemical and practical aspects. Archives of Oral Biology. 2007; 52: 1114-35.
Клиническая биохимия. Сборник инструкций. Новосибирск: ЗАО «Вектор-Бест»; 2011
Bel’skaya L.V., Kosenok V.K. The activity of metabolic enzymes in the saliva of lung cancer patients. National Journal of Physiology, Pharmacy and Pharmacology. 2017; 7(6): 646-53.
Elf S.E., Chen J. Targeting glucose metabolism in patients with cancer. Cancer. 2014; 120: 774.
Vander Heiden M.G., Cantley L.C, Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029.
Bezan A., Mrsic E., Krieger D., Stojakovic T., Pummer K., Zigeuner R., Hutterer G.C., Pichler M. The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma. The Journal of Urology. 2015; 194: 30-5.
Lee H., Choi Y.H., Sung H.H., Han D.H., Jeon H.G., Jeong B.C., Seo S.I., Jeon S.S., Lee H.M., Choi H.Y. De Ritis ratio (AST/ALT) as a significant prognostic factor in patients with upper tract urothelial cancer treated with surgery. Clinical Genitourinary Cancer; 2016.
Huijgen H.J., Sanders G., Koster R.W., Vreeken J., Bossuyt P. The clinical value of lactate dehydrogenase in serum: a quantitative review. Eur. Clin. Chem. Clin. Biochem. 1997; 35(8): 569-79.
Hermes A., Gatzemeier U., Waschki B., Reck M. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer — A retrospective single institution analysis. Respiratory Medicine. 2010; 104: 1937-42.
Wang Z-X., Yang L-., Qiu M-Z., Wang Z-Q., Zhou Y-X., Wang F., Zhang D-S., Wang F-H., Li Y-H., Xu R-H. Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms. Oncotarget. 2016; 26(7): 945-56.
Yao F., Zhao T., Zhong C., Zhu J., Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumor Biology. 2013; 34: 25-31.
Augoff K., Hryniewicz-Jankowska A., Tabola R. Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer. Cancer Letters. 2015; 358(1): 1-7.
Malathi M., Shrinivas B.R. Relevance of serum alkaline phosphatase as a diagnostic aid in lung pathology. Indian J. Physiol. Pharmacol. 2001; 45(1): 119-21.
Dokic-Lisanin M., Pantovic V., Jovanovic Z., Samardzic G., Jurisic V. Values of alkaline phosphatase and their isoenzyme profiles in patients with cancer in respect to bone and liver metastasis. Arch. Oncol. 2013; 21(1): 14-6.
Nakamura Y., Tomita N., Nishide T., Emi M., Horii A., Ogawa M., Mori T., Kosaki G., Okabe T., Fujisawa M., Ohsawa N., Kameya T., Matsubara K. Production of salivary type α-amylase in human lung cancer. Gene. 1989; 77: 107-12.
Lenler-Petersen P., Grove A., Brock A., Jelnes R. Alpha-amylase in resectable lung cancer. Eur. Respir J. 1994; 7: 941-5.
Turkeli S., Atici A.G., Kayhan S., Yilmaz Y.A. Analysis of pleural amylase levels in chest disease clinic. Journal of Experimental and Clinic Medicine. 2013; 30: 349-52.
Sakai M., Yamamoto T., Onizuka M., Sakakibara Y., Noguchi M. A direct measurement of serum amylase levels produced by lung cancer. Ann. Thorac. Surg. 2005; 79:1409-11.
Wang H., Wu Q. A case of amylase-producing small cell lung cancer. Clinical Biochemistry. 2016; 49(7-8): 613-6.
Grigoleit J-S., Kullmann J.S., Overbeck R., Schedlowski M., Engler H. Salivary α-amylase response to endotoxin administration in humans. Psychoneuroendocrinology. 2013; 38: 1819-23.
Whitfield J.B. Gamma Glutamil Transferase. Critical Reviews in Clinical Laboratory Sciences. 2001; 38(4): 263-355.
Pompella A., De Tata V., Paolicchi A., Zunino F. Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance. Biochemical Pharmacology. 2006; 71: 231-8.
Van Hemelrijck M., Jassem W., Walldius G., Fentiman I.S., Hammar N., Lambe M., Garmo H., Jungner I., Holmberg L. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons — the Swedish AMORIS study. European Journal of Cancer. 2011; 47: 2033-41.
Бельская Л.В., Косенок В.К., Массард Ж., Завьялов А.А. Состояние показателей липопероксидации и эндогенной интоксикации у больных раком легкого. Вестник РАМН. 2016; 71(4): 313-22